Piramal Pharma Stock Price Analysis and Quick Research Report. Is Piramal Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Piramal Pharma. 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Piramal Pharma has a PE ratio of 33.6940603663059 which is high and comparatively overvalued.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Piramal Pharma has ROA of 6.0169% which is a bad sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Piramal Pharma has a Current ratio of 1.5661.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Piramal Pharma has a ROE of 9.0585%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Piramal Pharma has a Debt to Equity ratio of 0.088 which means that the company has low proportion of debt in its capital.

• Sales growth: Piramal Pharma has reported revenue growth of -9.5295% which is poor in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Piramal Pharma for the current financial year is 13.0934481525551%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Piramal Pharma is Rs 0 and the yield is 0%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Piramal Pharma is Rs 5.2579. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Piramal Pharma in Ticker for free. Also, one can get the intrinsic value of Piramal Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Piramal Pharma FAQs

Q1. What is Piramal Pharma share price today?
Ans: The current share price of Piramal Pharma is Rs 177.16.

Q2. What is the market capitalisation of Piramal Pharma?
Ans: Piramal Pharma has a market capitalisation of Rs 23586.16347108 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Piramal Pharma?
Ans: The PE ratio of Piramal Pharma is 33.6940603663059 and the P/B ratio of Piramal Pharma is 2.92253532744075, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Piramal Pharma share?
Ans: The 52-week high share price of Piramal Pharma is Rs 220.85, and the 52-week low share price of Piramal Pharma is Rs 132.3.

Q5. Does Piramal Pharma pay dividends?
Ans: Currently, Piramal Pharma does not pay dividends. Dividend yield of Piramal Pharma is around 0%.

Q6. What are the face value and book value of Piramal Pharma shares?
Ans: The face value of Piramal Pharma shares is Rs 10, while the book value per share of Piramal Pharma is around Rs 60.6186. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Piramal Pharma?
Ans: Piramal Pharma has a total debt of Rs 709.89 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Piramal Pharma?
Ans: The ROE of Piramal Pharma is 9.0585% and ROCE of Piramal Pharma is 10.918%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Piramal Pharma a good buy for the long term?
Ans: The Piramal Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Piramal Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Piramal Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Piramal Pharma’s financials?
Ans: You can review Piramal Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.